LexaGene closes secured convertible bond deal, The Canadian Business Journal

BEVERLY, Massachusetts, November 1, 2022 (GLOBE NEWSWIRE) — LexaGene Holdings, Inc. (OTCQB: LXXGF; TSX-V: LXG) (“Lexagene” or “CompanyA molecular diagnostics company that has commercialized the MiQLab® system for automated multiplex PCR testing.Note) to Meridian LGH Holdings 2, LLC, our insider affiliate, in an aggregate principal amount of up to US$1,600,000. The maturity date is March 1, 2023 for him.

The debentures are collateralized against the Company’s assets and guaranteed by the Company’s subsidiaries.

The Debentures and the Company’s underlying common stock upon exercise of the conversion rights attached to the Debentures have not been and will not be registered under the Securities Act of 1933, as amended.U.S. Securities Law“), or provided in the United States or to a United States Person (as defined in Regulation S under the United States Securities Laws) or for the account or benefit thereof, unless registered in the United States under state securities laws. Subject to United States securities laws and applicable state securities laws, or exemptions from such registration, this press release constitutes an offer to sell or an offer to buy the securities referred to herein. does not constitute a solicitation of

For more information on LexaGene and MiQLab systems, or Subscribe for company updatesvisit www.lexagene.comor follow me twitter Also LinkedIn.

For more information on LexaGene and the MiQLab system, please visit: www.lexagene.com or follow me twitter Also LinkedIn.

About Lexagene Holdings
LexaGene is a molecular diagnostics company that has commercialized the MiQLab system for the rapid and easy detection of pathogens and other molecular markers. The system is designed for field use and uses real-time PCR chemistry. Our customers include biopharmaceutical companies, veterinary hospitals and reference laboratories. The MiQLab system offers excellent sensitivity, specificity and broad detection range.

TSX Venture Exchange Inc. has never waived the merits of the proposed transaction and has neither approved nor denied the contents of this press release. Neither TSX Venture Exchange nor its regulated service providers (as those terms are defined in the TSX Venture Exchange Policy) are responsible for the adequacy or accuracy of this release.

This news release contains forward-looking information that involves known and unknown risks, uncertainties and other factors that could cause actual events to differ materially from current expectations.Important factors such as the availability of funds, the results of financing, the success of technology development, the cost of procuring critical components, equipment performance, market acceptance of the technology, regulatory acceptance, and licensing issues affect the actual Results differ materially from our expectations disclosed in our documents filed with SEDAR from time to time (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements. These statements are made only as of the date of this press release. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

CBJ Newsmaker